Tag: restrictions

CALGARY, Alberta, June 25, 2026 (GLOBE NEWSWIRE) -- Petrus Resources Ltd. ("Petrus") (TSX: PRQ) is pleased to announce that the Toronto Stock Exchange (the "TSX") has accepted Petrus' notice of intention to renew its normal course issuer bid (the "NCIB"). The NCIB allows Petrus to purchase up to 7,424,183 common shares (representing 5% of Petrus' outstanding common shares as of June 19, 2026) over a period of twelve months commencing on June 30, 2026. On June 19, 2026, Petrus had 148,483,679 common shares outstanding. The NCIB will expire no later than June 29, 2027.

DENVER and MIAMI, June 24, 2026 (GLOBE NEWSWIRE) -- The Western Union Company (“Western Union”) (NYSE: WU) and International Money Express, Inc. (“Intermex”) (NASDAQ: IMXI) today provided an update on the approval process and timeline for Western Union’s pending acquisition of Intermex. To date, money transmission regulators in 51 applicable U.S. states and territories and in all international jurisdictions have provided their approval of or non-objection to the acquisition, and approval or non-objection is currently pending from one U.S. state. Western Union and Intermex remain actively engaged in discussions with regulators, including the New York State Department of Financial Services, to obtain the final regulatory approval. Western Union and Intermex anticipate closing the transaction as soon as reasonably practicable upon receipt of such approval as well as satisfaction of other customary closing conditions.

Fiscal 2026 Net Income Expected Between $15 Million and $18 Million
Adjusted EBITDA Expected between $75 Million and $77 Million, an increase of 26% to 30%
First Day Program Revenues Estimated to Increase 27% to 28%
Board of Directors Declares Quarterly Dividend of $0.08 per Common Share

NEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the pricing of an underwritten offering of 10,309,280 common shares in the capital of the Company (the “Common Shares”) at an offering price of US$4.85 per Common Share, for aggregate gross proceeds of US$50 million (the “Offering”).